The prevalence of therapeutic use exemptions (TUEs) among athletes competing in the Olympic and Paralympic Games has recently come to light thanks to a study by the World Anti-Doping Agency (WADA). The study, which analysed data from 2016–2022, aimed to provide a comprehensive overview of TUE utilisation and its implications for fairness and transparency in elite sports. The findings were published in the British Journal of Sports Medicine.
Therapeutic Use Exemptions allow athletes with legitimate medical conditions to use otherwise prohibited substances for treatment purposes. The International Standard for Therapeutic Use Exemptions (ISTUE), which oversees this system, ensures that athletes can receive necessary medical care without gaining an unfair advantage. However, the process has faced scrutiny over potential misuse, prompting WADA to conduct thorough investigations to ensure the integrity of the system.
The primary objective of the study was to evaluate the prevalence of TUEs at four recent editions of the Summer and Winter Olympic and Paralympic Games. Additionally, the study aimed to categorise the prohibited substances and methods associated with TUEs. Data was extracted from the Anti-Doping Administration and Management System (ADAMS), which consolidates doping control-related information globally.
The study revealed that, out of 28,583 athletes who competed in four Olympic Games, only 0.90% had valid TUEs. In the Paralympic Games, out of 9,852 athletes, the prevalence was slightly higher at 2.76%. This discrepancy is attributed to the higher prevalence of complex medical conditions among Paralympic athletes.
The substances most frequently associated with TUEs at the Summer Olympics were glucocorticoids (0.50% in Rio 2016) and stimulants (0.39% in Tokyo 2020). In contrast, at the Summer Paralympics, diuretics (0.79% in Rio) and stimulants (0.75% in Tokyo) were the most common. Winter Games showed similar trends but with significantly lower numbers.
A notable decline in TUE prevalence was observed between the Rio 2016 and Tokyo 2020 Games, with Olympic TUE prevalence dropping from 1.06% to 0.74% and Paralympic TUE prevalence dropping from 3.03% to 2.19%. Several factors contributed to this decline, including increased education and awareness about changing TUE requirements, and the impact of the Covid pandemic, which led to stricter safety measures and reduced athlete attendance.
The study’s findings reaffirm that TUEs are not widespread in elite sports. The low prevalence suggests that the TUE system is not being exploited for performance enhancement. Moreover, the study highlights the importance of continuous monitoring and transparency to maintain confidence in the sporting community.
Various medical conditions were associated with TUEs, with over 95% of narcotics prescribed for analgesic purposes and more than 90% of hormone and metabolic modulators used for treating diabetes. The use of stimulants, primarily for attention-deficit hyperactivity disorder (ADHD) and anaphylaxis, was also significant.
The results of this study align with previous research, reinforcing the notion that the TUE system is robust and not prone to misuse. However, continued vigilance is necessary to address any potential gaps. The study’s comprehensive evaluation of ADAMS TUE data provides valuable insights that can inform future policy and education initiatives in sport and anti-doping.
WADA’s commitment to ensuring the integrity of the TUE process is crucial for the promotion of fair competition, inclusion, and the health of athletes. By maintaining stringent controls and transparency, the sporting community can continue to trust that the TUE system supports those in genuine need while upholding the principles of clean sport.
